ASEAN Heart Journal

First online: 

Case Reports

Cholesterol Target Value Achievement and Lipid-

lowering Therapy in Patients with Stable or Acute

Coronary Heart Disease in Vietnam - Results from

the Dyslipidemia International Study II

Nguyen Lan Viet, Pham Nguyen Vinh, Vo Thanh Nhan, Do Quang Huan,

Pham Manh Hung, Dang Mai Tram, Baishali Ambegaonkar, Carl A Baxter,

Philippe Brudi, Martin Horack, Dominik Lautsch, Anselm Gitt.

13 September 2018

September 2018, 25:1

Case Reports

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

Reference Tools

References

1.World Health Organization. Disease and injury country estimates 2008 [Accessed July 2017]. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/.

2.Nguyen HN, Fujiyoshi A, Abbott RD, Miura K. Epidemiology of cardiovascular risk factors in Asian
countries. Circ J 2013;77:2851-9.

PubMed

 

3.Nguyen HL, Ha DA, Phan DT, et al. Sex differences in clinical characteristics, hospital management practices, and in-hospital outcomes in patients hospitalized in a Vietnamese hospital with a first acute myocardial infarction. PLoS One 2014;9:e95631.

CrossRef    PubMed
 

4.Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003;32:563-72.

PubMed

 

5.Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.

PubMed

 

6.Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016.

CrossRef    PubMed
 

7.Gitt AK, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis 2016;255:200-9.

CrossRef    PubMed
 

8.Chiang CE, Ferrieres J, Gotcheva NN, et al. Suboptimal control of lipid levels: results from 29 countries participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb 2015.

CrossRef    PubMed
 

9.Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol 2012;19:781-94.

CrossRef    PubMed
 

10.European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.

CrossRef    PubMed
 

11.Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic
equivalence of statins. J Clin Pharm Ther 2010;35:139-51.

CrossRef    PubMed
 

12.Nguyen HL, Nguyen QN, Ha DA, Phan DT, Nguyen NH, Goldberg RJ. Prevalence of comorbidities and their impact on hospital management and shortterm outcomes in Vietnamese patients hospitalized with a first acute myocardial infarction. PLoS One 2014;9:e108998.

CrossRef    PubMed

13.Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636-48.

CrossRef    PubMed
 

14.Chan RH, Chan PH, Chan KK, et al. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipidlowering
treatment in a Hong Kong regional centre. Hong Kong Med J 2012;18:395-406.

PubMed
 

15.Wang KF, Chang CC, Wang KL, et al. Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey. J Chin Med Assoc 2014;77:61-7.

CrossRef    PubMed
 

16.Sung J, Kim SH, Song HR, Chi MH, Park JE. Lipidlowering treatment practice patterns in korea:
comparison with the data obtained from the CEPHEUS Pan-Asian study. J Atheroscler Thromb 2014;21:1219-27.

PubMed
 

17.Munawar M, Hartono B, Rifqi S. LDL Cholesterol Goal Attainment in Hypercholesterolemia: CEPHEUS Indonesian Survey. Acta Cardiol Sin 2013;29:71-81.

PubMed

 

18.Nguyen T, Nguyen TH, Pham HT, et al. Physicians’ adherence to acute coronary syndrome prescribing guidelines in Vietnamese hospital practice: a crosssectional study. Trop Med Int Health 2015;20:627-37.

CrossRef    PubMed
 

19.Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.

PubMed
 

20.Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576-84.

CrossRef    PudMed

 

21.Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.

CrossRef    PubMed

 

22.Yu CC, Lai WT, Shih KC, et al. Efficacy, safety and tolerability of ongoing statin plus ezetimibe
versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an openlabel, randomized clinical trial. BMC Res Notes 2012;5:251.

CrossRef    PubMed
 

23.Setia S, Fung SS, Waters DD. Doctors’ knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore. Vasc Health Risk Manag 2015;11:303-10.

CrossRef    PubMed
 

24.Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, Sperling LS. Utilization of and adherence to guidelinerecommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J Am Coll Cardiol 2015;66:184-92.

CrossRef    PubMed
 

25.Chan JC, Kong AP, Bao W, Fayyad R, Laskey R. Safety of atorvastatin in Asian patients within clinical trials. Cardiovasc Ther 2016;34:431-40.

CrossRef    PubMed

 

26.Birmingham BK, Bujac SR, Elsby R, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol 2015;71:329-40.

CrossRef    PubMed


27.Li YF, Feng QZ, Gao WQ, Zhang XJ, Huang Y, Chen YD. The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report. BMC Cardiovasc Disord 2015;15:6.

CrossRef    PubMed


28.Truong QB et al. The 2015 National Heart Association guideline on Dyslipidemia Diagnosis and
Management. The Journal of Vietnamese Cardiology online: http://vnha.org.vn/cate.asp?cate_id=167, accessed on September 9, 2017

.

.

.

Tel No: +603-7931 7900
Fax No: +603-7932 1400

 

 

D-13A-06, Menara Suezcap 1, KL Gateway,
No.2 Jalan Kerinchi, Gerbang Kerinchi Lestari,
59200 Kuala Lumpur, Malaysia.

www.aseancardiology.org

ASEAN HEART Journal is Supported by Unrestricted Grant From 

Committed to therapeutic advances in cardiovascular research